$FBIO
Fortress Biotech, Inc. Stock $fbio

$fbio Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000114420418043295 Filed on August 09, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q2
Revenue	$6.815M	$5.903M	$4.404M
YoY Change	54.75%	112.49%	97.49%
Cost Of Revenue	$1.668M	$1.472M	$878.0K
YoY Change	89.98%	213.86%	170.99%
Gross Profit	$5.147M	$4.431M	$3.526M
YoY Change	45.97%	91.9%	84.99%
Gross Profit Margin	75.52%	75.06%	80.06%
Selling, General & Admin	$13.06M	$16.31M	$11.13M
YoY Change	17.26%	59.11%	28.94%
% of Gross Profit	253.66%	368.13%	315.77%
Research & Development	$1.000K	$24.96M	$1.800M
YoY Change	-99.94%	196.98%	-12.62%
% of Gross Profit	0.02%	563.26%	51.05%
Depreciation & Amortization	$440.0K	$196.0K	$180.0K
YoY Change	144.44%	-71.26%	119.51%
% of Gross Profit	8.55%	4.42%	5.1%
Operating Expenses	$88.43M	$40.08M	$73.89M
YoY Change	19.68%	-35.63%	325.49%
Operating Profit	-$32.21M	-$34.17M	-$25.50M
YoY Change	26.35%	78.68%	49.6%
Interest Expense	$2.144M	$2.083M	$1.380M
YoY Change	55.36%	198.42%	160.87%
% of Operating Profit
Other Income/Expense, Net	-$9.681M	-$1.970M	$244.0K
YoY Change	-4067.62%	-165.34%	-119.47%
Pretax Income	-$34.28M	-$36.14M	-$22.95M
YoY Change	49.37%	148.23%	40.02%
Income Tax	$1.438M		$0.00
% Of Pretax Income
Net Earnings	-$21.61M	-$21.02M	-$17.37M
YoY Change	24.45%	75.41%	39.16%
Net Earnings / Revenue	-317.11%	-356.06%	-394.3%
Basic Earnings Per Share		-$0.49
Diluted Earnings Per Share	-$498.2K	-$0.49	-$428.4K
COMMON SHARES
Basic Shares Outstanding		42.52M	50.33M shares
Diluted Shares Outstanding		42.52M

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$137.4M	$165.3M	$167.8M
YoY Change	-18.12%	22.26%	135.34%
Cash & Equivalents	$116.8M	$120.9M	$161.2M
Short-Term Investments	$38.80M	$41.30M	$23.40M
Other Short-Term Assets	$14.70M	$15.30M	$12.90M
YoY Change	13.95%	61.05%	706.25%
Inventory	$300.0K	$222.0K	$299.0K
Prepaid Expenses
Receivables	$5.300M	$8.314M	$3.336M
Other Receivables	$13.80M	$11.00M	$5.900M
Total Short-Term Assets	$171.5M	$200.2M	$190.2M
YoY Change	-9.82%	31.86%	148.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.532M	$2.119M	$7.329M
YoY Change	-65.45%	-71.36%	62.87%
Goodwill		$18.65M	$18.65M
YoY Change		0.0%
Intangibles
YoY Change
Long-Term Investments	$600.0K	$1.300M	$300.0K
YoY Change	100.0%	333.33%	20.0%
Other Assets	$18.40M	$936.0K	$16.30M
YoY Change	12.88%	-94.26%	11.64%
Total Long-Term Assets	$65.40M	$64.92M	$59.62M
YoY Change	9.69%	8.02%	177.79%
TOTAL ASSETS
Total Short-Term Assets	$171.5M	$200.2M	$190.2M
Total Long-Term Assets	$65.40M	$64.92M	$59.62M
Total Assets	$236.9M	$265.1M	$249.8M
YoY Change	-5.16%	25.09%	154.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$38.20M	$44.80M	$25.00M
YoY Change	52.8%	79.92%	390.2%
Accrued Expenses	$17.51M	$21.71M	$12.37M
YoY Change	41.51%	95.27%	45.56%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$10.60M	$12.70M	$6.200M
YoY Change	70.97%	139.62%
Total Short-Term Liabilities	$62.20M	$79.30M	$53.50M
YoY Change	16.26%	50.19%	274.13%
LONG-TERM LIABILITIES
Long-Term Debt	$73.50M	$73.40M	$40.70M
YoY Change	80.59%	164.03%	86.7%
Other Long-Term Liabilities	$5.000M	$4.759M	$5.026M
YoY Change	-0.52%	-4.82%	35.84%
Total Long-Term Liabilities	$78.50M	$4.759M	$5.026M
YoY Change	1461.88%	-85.49%	-80.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$62.20M	$79.30M	$53.50M
Total Long-Term Liabilities	$78.50M	$4.759M	$5.026M
Total Liabilities	$192.9M	$157.5M	$99.23M
YoY Change	94.4%	-4.06%	58.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$354.8M	-$333.1M	-$274.6M
YoY Change	29.19%
Common Stock	$54.00K	$52.00K	$800.0K
YoY Change	-93.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$43.93M	$41.65M	$72.27M
YoY Change
Total Liabilities & Shareholders Equity	$236.9M	$265.1M	$249.8M
YoY Change	-5.2%	25.09%	154.69%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q2
OPERATING ACTIVITIES
Net Income	-$21.61M	-$21.02M	-$17.37M
YoY Change	24.45%	75.41%	39.16%
Depreciation, Depletion And Amortization	$440.0K	$196.0K	$180.0K
YoY Change	144.44%	-71.26%	119.51%
Cash From Operating Activities	-$24.09M	-$27.84M	-$23.88M
YoY Change	0.88%	142.65%	223.58%
INVESTING ACTIVITIES
Capital Expenditures	-$3.840M	$765.0K	-$190.0K
YoY Change	1921.05%	193.1%	-91.2%
Acquisitions
YoY Change
Other Investing Activities	$1.660M	-$1.080M	-$20.03M
YoY Change	-108.29%	58.82%	872.33%
Cash From Investing Activities	-$2.190M	-$1.840M	-$20.23M
YoY Change	-89.17%	95.33%	379.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$34.20M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.720M	39.66M	54.42M
YoY Change	-95.0%	-31.82%	3480.26%
NET CHANGE
Cash From Operating Activities	-24.09M	-27.84M	-23.88M
Cash From Investing Activities	-2.190M	-1.840M	-20.23M
Cash From Financing Activities	2.720M	39.66M	54.42M
Net Change In Cash	-23.56M	9.971M	10.31M
YoY Change	-328.52%	-78.2%	-202.28%
FREE CASH FLOW
Cash From Operating Activities	-$24.09M	-$27.84M	-$23.88M
Capital Expenditures	-$3.840M	$765.0K	-$190.0K
Free Cash Flow	-$20.25M	-$28.61M	-$23.69M
YoY Change	-14.52%	143.77%	353.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	51000	USD
CY2017Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	222000	USD
CY2018Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	73000	USD
CY2018Q2	us-gaap	Deferred Revenue DeferredRevenue	650000	USD
CY2017Q4	us-gaap	Deferred Revenue DeferredRevenue	0	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	73890000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-23193000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-24597000	USD
CY2017Q2	us-gaap	Revenues Revenues	50697000	USD
CY2017Q2	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	0	USD
CY2018Q2	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	42000	USD
CY2018Q2	us-gaap	Revenues Revenues	63834000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	88431000	USD
	us-gaap	Operating Expenses OperatingExpenses	136149000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-40770000	USD
	us-gaap	Revenues Revenues	95379000	USD
	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	0	USD
	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	187000	USD
	us-gaap	Revenues Revenues	119259000	USD
	us-gaap	Operating Expenses OperatingExpenses	179342000	USD
CY2018Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	96265000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	120502000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	8623000	USD
	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	22657000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-42629000	USD
	fbio	Issuance Of Common Stock For At Market Offering IssuanceOfCommonStockForAtMarketOffering	4070000	USD
	fbio	Stock Issued During Period Value Cash Less Exercise Of Warrants StockIssuedDuringPeriodValueCashLessExerciseOfWarrants	181000	USD
	fbio	Adjustments To Additional Paid In Capital At Market Offering Costs AdjustmentsToAdditionalPaidInCapitalAtMarketOfferingCosts	-141000	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
	fbio	Adjustments To Additional Paid In Capital Acquisition Of Business AdjustmentsToAdditionalPaidInCapitalAcquisitionOfBusiness	-767000	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1172000	USD
	fbio	Stock Issued During Period Value Interest Expense StockIssuedDuringPeriodValueInterestExpense	1297000	USD
	fbio	Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance	0	USD
	us-gaap	Profit Loss ProfitLoss	-73934000	USD
	us-gaap	Profit Loss ProfitLoss	-37511000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	481000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	702000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8623000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7736000	USD
	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-825000	USD
	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-511000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	248000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55301000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35359000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4663000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	454000	USD
	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	0	USD
	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	3000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4264000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21165000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1213000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2590000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	256000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	3000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	3095000	USD
	fbio	Payment For Research And Development Licenses PaymentForResearchAndDevelopmentLicenses	75000	USD
	fbio	Payment For Research And Development Licenses PaymentForResearchAndDevelopmentLicenses	665000	USD
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	98000	USD
	us-gaap	Cost Of Goods Sold Amortization CostOfGoodsSoldAmortization	266000	USD
	us-gaap	Cost Of Goods Sold Amortization CostOfGoodsSoldAmortization	267000	USD
	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	110000	USD
	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	-285000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2437000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1506000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	128000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	96000	USD
	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	157000	USD
	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	-185000	USD
	fbio	Amortization Of Forgivable Loans To Registered Representatives AmortizationOfForgivableLoansToRegisteredRepresentatives	310000	USD
	fbio	Amortization Of Forgivable Loans To Registered Representatives AmortizationOfForgivableLoansToRegisteredRepresentatives	362000	USD
	fbio	Amortization Of Deferred Clearing Credit AmortizationOfDeferredClearingCredit	-105000	USD
	fbio	Amortization Of Deferred Clearing Credit AmortizationOfDeferredClearingCredit	-104000	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	46000	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	256000	USD
	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	7931000	USD
	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	-5794000	USD
	us-gaap	Increase Decrease In Broker Dealer Related Receivables Payables Net IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet	4017000	USD
	us-gaap	Increase Decrease In Broker Dealer Related Receivables Payables Net IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet	-544000	USD
	us-gaap	Increase Decrease In Other Loans IncreaseDecreaseInOtherLoans	292000	USD
	us-gaap	Increase Decrease In Other Loans IncreaseDecreaseInOtherLoans	47000	USD
	us-gaap	Increase Decrease In Marketable Securities Restricted IncreaseDecreaseInMarketableSecuritiesRestricted	1827000	USD
	us-gaap	Increase Decrease In Marketable Securities Restricted IncreaseDecreaseInMarketableSecuritiesRestricted	1049000	USD
	us-gaap	Increase Decrease In Financial Instruments Sold Not Yet Purchased IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased	-143000	USD
	us-gaap	Increase Decrease In Financial Instruments Sold Not Yet Purchased IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased	-221000	USD
	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	-3000	USD
	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	259000	USD
	us-gaap	Payments For Proceeds From Businesses And Interest In Affiliates PaymentsForProceedsFromBusinessesAndInterestInAffiliates	187000	USD
	us-gaap	Payments For Proceeds From Businesses And Interest In Affiliates PaymentsForProceedsFromBusinessesAndInterestInAffiliates	19000	USD
	us-gaap	Depreciation Depreciation	831000	USD
	us-gaap	Depreciation Depreciation	543000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1388000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	819000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	20038000	USD
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	47000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1154000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1721000	USD
	fbio	Change In Fair Value Of Subsidiaries Assets And Liabilities ChangeInFairValueOfSubsidiariesAssetsAndLiabilities	10000	USD
	fbio	Change In Fair Value Of Subsidiaries Assets And Liabilities ChangeInFairValueOfSubsidiariesAssetsAndLiabilities	10000	USD
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	8000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	36002000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	978000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	189000	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-99000	USD
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	24000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	650000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-15527000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	56060000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1000	USD
	fbio	Convertible Notes Conversion Converted Instrument Amount ConvertibleNotesConversionConvertedInstrumentAmount	0	USD
	fbio	Convertible Notes Conversion Converted Instrument Amount ConvertibleNotesConversionConvertedInstrumentAmount	201000	USD
	fbio	Issue Of Common Stock For Acquiring License Value IssueOfCommonStockForAcquiringLicenseValue	0	USD
	fbio	Issue Of Common Stock For Acquiring License Value IssueOfCommonStockForAcquiringLicenseValue	1682000	USD
	us-gaap	Interest Paid Net InterestPaidNet	5000	USD
	us-gaap	Interest Paid Net InterestPaidNet	8000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1297000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	187000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	19000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	1172000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	USD
	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	4070000	USD
	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	0	USD
	fbio	Payment Of Cost Related To Atthemarket Offering PaymentOfCostRelatedToAtthemarketOffering	141000	USD
	fbio	Payment Of Cost Related To Atthemarket Offering PaymentOfCostRelatedToAtthemarketOffering	0	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	23011000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	93853000	USD
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	354000	USD
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	862000	USD
	us-gaap	Proceeds From Unsecured Lines Of Credit ProceedsFromUnsecuredLinesOfCredit	0	USD
	us-gaap	Proceeds From Unsecured Lines Of Credit ProceedsFromUnsecuredLinesOfCredit	2500000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	404000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	21707000	USD
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	127000	USD
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	0	USD
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	44038000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	112584000	USD
	fbio	Issuance Of Warrants In Conjunction With Subordinated Note Financing IssuanceOfWarrantsInConjunctionWithSubordinatedNoteFinancing	0	USD
	fbio	Issuance Of Warrants In Conjunction With Subordinated Note Financing IssuanceOfWarrantsInConjunctionWithSubordinatedNoteFinancing	1197000	USD
	us-gaap	Stock Issued1 StockIssued1	990000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2018Q1	fbio	National Investment Banking Expenses NationalInvestmentBankingExpenses	100000	USD
CY2018Q1	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	300000	USD
CY2017Q1	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	400000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2922000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2872000	USD
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	803000	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	475000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2397000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2119000	USD
	us-gaap	Investments In And Advances To Affiliates At Fair Value Period Increase Decrease InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease	800000	USD
CY2018Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	565000	USD
CY2018Q2	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	565000	USD
CY2018Q2	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	10573000	USD
CY2017Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	1390000	USD
CY2017Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	1390000	USD
CY2017Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	14846000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	21833000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	825000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-110000	USD
	fbio	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisDerivativeLiabilityGainLossIncludedInEarnings	-7931000	USD
CY2018Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	11138000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	-4076000	USD
CY2018Q2	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1000	USD
CY2017Q2	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1800000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	98000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	3094000	USD
CY2017Q4	us-gaap	Long Term Debt LongTermDebt	67544000	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1035000	USD
CY2018Q2	us-gaap	Long Term Debt LongTermDebt	85064000	USD
CY2018Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1035000	USD
CY2017Q4	us-gaap	Notes Payable NotesPayable	66509000	USD
CY2018Q2	us-gaap	Notes Payable NotesPayable	84029000	USD
CY2018Q2	us-gaap	Interest Expense InterestExpense	2144000	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	1380000	USD
	us-gaap	Interest Expense InterestExpense	4227000	USD
	us-gaap	Interest Expense InterestExpense	2078000	USD
CY2018Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3569000	USD
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5279000	USD
CY2018Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1535000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1625000	USD
CY2018Q2	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	5143000	USD
CY2017Q4	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	4046000	USD
CY2018Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	779000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1030000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17509000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17632000	USD
CY2018Q2	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	3365000	USD
CY2017Q4	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	3059000	USD
CY2018Q2	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	4987000	USD
CY2017Q4	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	4739000	USD
CY2018Q2	fbio	Accrued Expenses Related Party AccruedExpensesRelatedParty	73000	USD
CY2017Q4	fbio	Accrued Expenses Related Party AccruedExpensesRelatedParty	95000	USD
CY2018Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1268000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1411000	USD
	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	83637000	USD
CY2018Q2	us-gaap	Minority Interest MinorityInterest	52332000	USD
CY2017	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	100889000	USD
CY2017	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-32960000	USD
CY2017Q4	us-gaap	Minority Interest MinorityInterest	67929000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17748353	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14707298	shares
CY2018Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3570000	USD
CY2017Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	4807000	USD
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	8623000	USD
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	7736000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.78
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1351080000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.78
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	719324000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y5M5D
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.75
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	719324000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y5M16D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y11M12D
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1110501	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1110501	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1085501	shares
	fbio	Sharebased Compensation Arrangement By Sharebased Payment Other Than Options Forfeited Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerm	P0Y
CY2018Q2	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	43000	USD
CY2017Q2	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	40000	USD
CY2018Q1	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	1700000	USD
CY2017Q3	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	2400000	USD
CY2018Q1	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	400000	USD
CY2017Q1	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	1000000	USD
CY2018Q1	us-gaap	Legal Fees LegalFees	0	USD
CY2017Q1	us-gaap	Legal Fees LegalFees	300000	USD
	fbio	Lease Sharing Agreements Contributions To Property Under Lease LeaseSharingAgreementsContributionsToPropertyUnderLease	96000	USD
	us-gaap	Noninterest Expense Transfer Agent And Custodian Fees NoninterestExpenseTransferAgentAndCustodianFees	1700000	USD
	fbio	Annual Management Services Agreement Fee Incomeexpense AnnualManagementServicesAgreementFeeIncomeexpense	0	USD
CY2018Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1668000	USD
CY2018Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2910000	USD
CY2018Q2	fbio	Research And Development Expenses Including Intangible Assets ResearchAndDevelopmentExpensesIncludingIntangibleAssets	17489000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10146000	USD
CY2017Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	878000	USD
CY2017Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2610000	USD
CY2017Q2	fbio	Research And Development Expenses Including Intangible Assets ResearchAndDevelopmentExpensesIncludingIntangibleAssets	13483000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8524000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3140000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5670000	USD
	fbio	Research And Development Expenses Including Intangible Assets ResearchAndDevelopmentExpensesIncludingIntangibleAssets	42544000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20934000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1347000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4877000	USD
	fbio	Research And Development Expenses Including Intangible Assets ResearchAndDevelopmentExpensesIncludingIntangibleAssets	21887000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16509000	USD
CY2018Q2	fbio	Return Reserve ReturnReserve	700000	USD
CY2017Q2	fbio	Return Reserve ReturnReserve	300000	USD
	fbio	Revenue Recognition Milestone Method Payments Due RevenueRecognitionMilestoneMethodPaymentsDue	500000	USD
CY2018Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	6689000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	12198000	USD
CY2018Q2	us-gaap	Brokerage Commissions Revenue BrokerageCommissionsRevenue	31407000	USD
CY2018Q2	us-gaap	Underwriting Income Loss UnderwritingIncomeLoss	6893000	USD
CY2018Q2	fbio	Private Placement Revenue PrivatePlacementRevenue	3484000	USD
CY2018Q2	us-gaap	Investment Advisory Fees InvestmentAdvisoryFees	833000	USD
CY2018Q2	us-gaap	Revenue Other Financial Services RevenueOtherFinancialServices	-4000	USD
CY2018Q2	fbio	Revenue From Contracts With Customers Excluding Other Revenue RevenueFromContractsWithCustomersExcludingOtherRevenue	42613000	USD
CY2018Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	14406000	USD
CY2018Q2	fbio	Revenue From Contracts With Customers Including Other Revenue RevenueFromContractsWithCustomersIncludingOtherRevenue	57019000	USD
	us-gaap	Brokerage Commissions Revenue BrokerageCommissionsRevenue	57025000	USD
	us-gaap	Underwriting Income Loss UnderwritingIncomeLoss	9593000	USD
	fbio	Private Placement Revenue PrivatePlacementRevenue	13299000	USD
	us-gaap	Investment Advisory Fees InvestmentAdvisoryFees	2147000	USD
	us-gaap	Revenue Other Financial Services RevenueOtherFinancialServices	156000	USD
	fbio	Revenue From Contracts With Customers Excluding Other Revenue RevenueFromContractsWithCustomersExcludingOtherRevenue	82220000	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	24321000	USD
	fbio	Revenue From Contracts With Customers Including Other Revenue RevenueFromContractsWithCustomersIncludingOtherRevenue	106541000	USD
CY2018Q2	us-gaap	Preferred Stock Value PreferredStockValue	1000	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	54000	USD
CY2018Q2	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	776000	USD
CY2017Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	500000	USD
CY2018Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	397858000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	364148000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-354756000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-312127000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	43933000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	52573000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	236866000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	245950000	USD
CY2018Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	0	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	973000	USD
CY2018Q2	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	1035000	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	62000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2017Q4	fbio	Preferred Stock Shares Designated PreferredStockSharesDesignated	5000000	shares
CY2018Q2	fbio	Preferred Stock Shares Designated PreferredStockSharesDesignated	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000000	shares
CY2018Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000000	shares
CY2018Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1000000	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50991285	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50991285	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53987074	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53987074	shares
CY2017Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	158015	shares
CY2018Q2	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	259813	shares
CY2018Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	294000	USD
CY2017Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	190000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	572000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	326000	USD
CY2018Q2	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	2144000	USD
CY2017Q2	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	1380000	USD
	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	4227000	USD
	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	2078000	USD
CY2018Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	6866000	USD
CY2017Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1452000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	7931000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5794000	USD
CY2018Q2	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	-140000	USD
CY2017Q2	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	-188000	USD
CY2018Q2	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-707000	USD
CY2017Q2	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	157000	USD
CY2018Q2	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-118000	USD
CY2017Q2	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	13000	USD
	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-112000	USD
	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	13000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9681000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	244000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12413000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3259000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-34278000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-22949000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-72496000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-37511000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1438000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1438000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q2	us-gaap	Profit Loss ProfitLoss	-35716000	USD
CY2017Q2	us-gaap	Profit Loss ProfitLoss	-22949000	USD
CY2018Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14105000	USD
CY2017Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5584000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-31305000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-8164000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-21611000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-17365000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-29347000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.99
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.73
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43377629	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40551844	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42948780	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40457524	shares
	fbio	Adjustments To Additional Paid In Capital Stock Issued For License Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses	23000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	128000	USD
	fbio	Unpaid Debt Offering Cost UnpaidDebtOfferingCost	5000	USD
	fbio	Unpaid Debt Offering Cost UnpaidDebtOfferingCost	79000	USD
	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	128000	USD
	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	42000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	14340000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	12997000	USD
CY2018Q2	fbio	Deferred Coupon Funding DeferredCouponFunding	1777000	USD
CY2017Q4	fbio	Deferred Coupon Funding DeferredCouponFunding	1087000	USD
	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	0	USD
	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	18967000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	4076000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1939000	USD
CY2018Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	100000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	500000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	27000	USD
	fbio	Payment Of Debt Issuance Costs Associated With Subsidiary Convertible Notes PaymentOfDebtIssuanceCostsAssociatedWithSubsidiaryConvertibleNotes	0	USD
	fbio	Payment Of Debt Issuance Costs Associated With Subsidiary Convertible Notes PaymentOfDebtIssuanceCostsAssociatedWithSubsidiaryConvertibleNotes	4000	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	750000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	-13615000	USD
	fbio	Description Of Fee Paid DescriptionOfFeePaid	NSC received a fee of approximately $1.8 million, or 8% on the gross proceeds raised of $23.0 million. The fees were eliminated in consolidation.
	us-gaap	Business Combination Contingent Consideration Arrangements Description BusinessCombinationContingentConsiderationArrangementsDescription	Fortress contended that no such payment is due because a condition of the EUR 2.5 million payment was the delivery of a Clinical Study Report that addressed the primary and secondary objectives of a Phase II trial, and Fortress contended that Dr. Falk Pharma failed to deliver such a Clinical Study Report. Dr. Falk Pharma filed a lawsuit against Fortress in the above-referenced Court in Frankfurt, Germany to recover the EUR 2.5 million plus interest and attorneys fees, and Fortress filed an answer to the complaint, denying that it had any liability to Dr. Falk Pharma.
	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	700000	USD
	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	1000000	USD
	us-gaap	Legal Fees LegalFees	300000	USD
	us-gaap	Legal Fees LegalFees	800000	USD
	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	81000	USD
	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	75000	USD
	us-gaap	Adjustments To Additional Paid In Capital Income Tax Deficiency From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation	-82000	USD
	fbio	Common Shares Issuable For Interest Expenses CommonSharesIssuableForInterestExpenses	978000	USD
	fbio	Common Shares Issued For Interest Expenses CommonSharesIssuedForInterestExpenses	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	13615000	USD
	fbio	Common Shares Issuable For Opus Interest Expenses CommonSharesIssuableForOpusInterestExpenses	287000	USD
	fbio	Issuance Of Stock For Service Of Opus Interest Expenses IssuanceOfStockForServiceOfOpusInterestExpenses	-287000	USD
	fbio	Issuance Of Stock For Service Of Opus Interest Expenses IssuanceOfStockForServiceOfOpusInterestExpenses	0	USD
	us-gaap	Payments For Mortgage Deposits PaymentsForMortgageDeposits	343000	USD
	us-gaap	Payments For Mortgage Deposits PaymentsForMortgageDeposits	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	45000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	82000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
	fbio	Reclassification Of Warrant Liability From Debt To Equity ReclassificationOfWarrantLiabilityFromDebtToEquity	13615000	USD
	fbio	Reclassification Of Warrant Liability From Debt To Equity ReclassificationOfWarrantLiabilityFromDebtToEquity	0	USD
	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	45000	USD
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	314000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	181000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	132343000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	105184000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	116816000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	161244000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	818000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><b>Use of Estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived and intangible assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, derivative warrant liabilities, revenue with customers, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name	View Source	Status
0001144204-18-043295-index-headers.html	Edgar Link	pending
0001144204-18-043295-index.html	Edgar Link	pending
0001144204-18-043295.txt	Edgar Link	pending
0001144204-18-043295-xbrl.zip	Edgar Link	pending
fbio-20180630.xml	Edgar Link	completed
fbio-20180630.xsd	Edgar Link	pending
fbio-20180630_cal.xml	Edgar Link	unprocessable
fbio-20180630_def.xml	Edgar Link	unprocessable
fbio-20180630_lab.xml	Edgar Link	unprocessable
fbio-20180630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv499568_10q.htm	Edgar Link	pending
tv499568_ex31-1.htm	Edgar Link	pending
tv499568_ex31-2.htm	Edgar Link	pending
tv499568_ex32-1.htm	Edgar Link	pending
tv499568_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBIO
Fortress Biotech, Inc. Stock $fbio

2018 Q2 Form 10-Q Financial Statement

#000114420418043295 Filed on August 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO Fortress Biotech, Inc. Stock $fbio

2018 Q2 Form 10-Q Financial Statement

#000114420418043295 Filed on August 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO
Fortress Biotech, Inc. Stock $fbio